Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Inhaled THC/CBD (Qixleef) in Healthy Volunteers
NCT04461756Phase 1Completed
- Sponsor
- Tetra Bio-Pharma Inc.
- Start
- Nov 2018
- Primary completion
- Nov 2018
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of qixleef in cancer pain and fibromyalgia (FM), sponsored by Tetra Bio-Pharma Inc. Primary endpoints: Assessment of adverse events at 5 days, Biochemistry test results at 5 days and 5 more. Started Nov 2018; status: completed.
02
Drugs
qixleef
03
Conditions
cancer painfibromyalgia (FM)
Beyond the preview
Go deeper on NCT04461756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04461756.